Microparticles as novel biomarkers and therapeutic targets in coronary heart disease

Chinese Medical Journal

Volumn 128, Issue 2, 2015, Pages 267-272

  Zhou, Bo Da ^a   Guo, Ge ^a   Zheng, Le Min ^b   Zu, Ling Yun ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Coagulation; Coronary heart disease; Endothelial function; Inflammation; Microparticle

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CD51 ANTIGEN; CLOPIDOGREL; CYCLOOXYGENASE 2; CYCLOPAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 5; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOPLASTIN; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE ADHERENCE; LEUKOCYTE MICROPARTICLE; PLATELET MICROPARTICLE; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH; BLOOD; CORONARY ARTERY DISEASE; INFLAMMATION; MEMBRANE MICROPARTICLE; METABOLISM;

BIOLOGICAL MARKERS; CELL-DERIVED MICROPARTICLES; CORONARY DISEASE; HUMANS; INFLAMMATION;

EID: 84925957526     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.149231     Document Type: Article

References (87)

1. Hargett LA, Bauer NN. On the origin of microparticles: From "platelet dust" to mediators of intercellular communication. Pulm Circ 2013;3:329-40.
2. Takeshita J, Mohler ER, Krishnamoorthy P, Moore J, Rogers WT, Zhang L, et al. Endothelial cell-, platelet-, and monocyte/ macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc 2014;3:e000507.
3. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48:180-6.
4. Morel O, Jesel L, Freyssinet JM, Toti F. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011;31:15-26.
5. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008;123:8-23.
6. Empana JP, Boulanger CM, Tafflet M, Renard JM, Leroyer AS, Varenne O, et al. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. Eur Heart J Acute Cardiovasc Care 2014; Epub ahead of print.
7. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/annexin V+microparticles correlate with cardiovascular outcomes. Eur Heart J 2011;32:2034-41.
8. Lee ST, Chu K, Jung KH, Kim JM, Moon HJ, Bahn JJ, et al. Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One 2012;7:e35713.
9. Biasucci LM, Porto I, Di Vito L, De Maria GL, Leone AM, Tinelli G, et al. Differences in microparticle release in patients with acute coronary syndrome and stable angina. Circ J 2012;76:2174-82.
10. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R, et al. Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb 2010;17:342-9.
11. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009;54:601-8.
12. Headland SE, Jones HR, D'Sa AS, Perretti M, Norling LV. Cutting-edge analysis of extracellular microparticles using Image Stream (X) imaging flow cytometry. Sci Rep 2014;4:5237.
13. van der Pol E, Hoekstra AG, Sturk A, Otto C, van Leeuwen TG, Nieuwland R. Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost 2010;8:2596-607.
14. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biró E, Nieuwland R, et al. Measuring circulating cell-derived microparticles. J Thromb Haemost 2004;2:1842-51.
15. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 2014;383:1933-43.
16. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: A clinical update. Curr Cardiol Rev 2013;9:331-9.
17. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999;340:115-26.
18. Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008;197:757-67.
19. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001;104:2649-52.
20. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-Modulation by statins. Endothelium 2003;10:23-33.
21. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, Leftheriotis G, et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008;173:1210-9.
22. Werner N, Wassmann S, Ahlers P, Kosiol S, Nickenig G. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006;26:112-6.
23. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003;145:962-70.
24. Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow J, et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol 2004;97:439-46.
25. Agouni A, Mostefai HA, Porro C, Carusio N, Favre J, Richard V, et al. Sonic Hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. FASEB J 2007;21:2735-41.
26. Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, et al. Sonic Hedgehog myocardial gene therapy: Tissue repair through transient reconstitution of embryonic signaling. Nat Med 2005;11:1197-204.
27. Asai J, Takenaka H, Kusano KF, Ii M, Luedemann C, Curry C, et al. Topical Sonic Hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. Circulation 2006;113:2413-24.
28. Palladino M, Gatto I, Neri V, Stigliano E, Smith RC, Pola E, et al. Combined therapy with Sonic Hedgehog gene transfer and bone marrow-derived endothelial progenitor cells enhances angiogenesis and myogenesis in the ischemic skeletal muscle. J Vasc Res 2012;49:425-31.
29. Liu H, Ding L, Zhang Y, Ni S. Circulating endothelial microparticles involved in lung function decline in a rat exposed in cigarette smoke maybe from apoptotic pulmonary capillary endothelial cells. J Thorac Dis 2014;6:649-55.
30. Tousoulis D, Papageorgiou N, Androulakis E, Siasos G, Latsios G, Tentolouris K, et al. Diabetes mellitus-associated vascular impairment: Novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol 2013;62:667-76.
31. Bona RD, Liuzzo G, Pedicino D, Crea F. Anti-inflammatory treatment of acute coronary syndromes. Curr Pharm Des 2011;17:4172-89.
32. Tomey MI, Narula J, Kovacic JC. Advances in the understanding of plaque composition and treatment options: year in review. J Am Coll Cardiol 2014;63:1604-16.
33. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res 2014;114:1852-66.
34. Azevedo LC, Pedro MA, Laurindo FR. Circulating microparticles as therapeutic targets in cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007;2:41-51.
35. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327:580-3.
36. Tushuizen ME, Diamant M, Sturk A, Nieuwland R. Cell-derived microparticles in the pathogenesis of cardiovascular disease: Friend or foe? Arterioscler Thromb Vasc Biol 2011;31:4-9.
37. Andriantsitohaina R, Gaceb A, Vergori L, Martínez MC. Microparticles as regulators of cardiovascular inflammation. Trends Cardiovasc Med 2012;22:88-92.
38. Benameur T, Andriantsitohaina R, Martínez MC. Therapeutic potential of plasma membrane-derived microparticles. Pharmacol Rep 2009;61:49-57.
39. Businaro R, Tagliani A, Buttari B, Profumo E, Ippoliti F, Di Cristofano C, et al. Cellular and molecular players in the atherosclerotic plaque progression. Ann N Y Acad Sci 2012;1262:134-41.
40. Seizer P, May AE. Therapeutic potential and strategies against leukocyte-platelet interaction in atherosclerosis. Curr Vasc Pharmacol 2012;10:550-4.
41. Reininger AJ, Heijnen HF, Schumann H, Specht HM, Schramm W, Ruggeri ZM. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006;107:3537-45.
42. Nauta AJ, Trouw LA, Daha MR, Tijsma O, Nieuwland R, Schwaeble WJ, et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002;32:1726-36.
43. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 2006;109:248-56.
44. Biró E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, et al. Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007;66:1085-92.
45. van der Zee PM, Biró E, Trouw LA, Ko Y, de Winter RJ, Hack CE, et al. C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. Clin Immunol 2010;135:490-5.
46. Tesse A, Al-Massarani G, Wangensteen R, Reitenbach S, Martínez MC, Andriantsitohaina R. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. J Pharmacol Exp Ther 2008;324:539-47.
47. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. Thromb Res 2012;129:235-40.
48. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, et al. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007;97:425-34.
49. Maly M, Hrachovinova I, Tomasov P, Salaj P, Hajek P, Veselka J. Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma: A pilot study. Eur J Haematol 2009;82:148-53.
50. Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 2005;16:368-71.
51. Zwicker JI, Trenor CC 3rd, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011;31:728-33.
52. Kleinjan A, Böing AN, Sturk A, Nieuwland R. Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology. Thromb Res 2012;130 Suppl 1:S71-3.
53. Huisse MG, Ajzenberg N, Feldman L, Guillin MC, Steg PG. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009;101:734-40.
54. Leroyer AS, Isobe H, Lesèche G, Castier Y, Wassef M, Mallat Z, et al. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007;49:772-7.
55. Angelillo-Scherrer A. Leukocyte-derived microparticles in vascular homeostasis. Circ Res 2012;110:356-69.
56. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004;10:171-8.
57. Viera AJ, Mooberry M, Key NS. Microparticles in cardiovascular disease pathophysiology and outcomes. J Am Soc Hypertens 2012;6:243-52.
58. Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: New players in the field of vascular disease? Eur J Clin Invest 2004;34:392-401.
59. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 2007;21:157-71.
60. Shai E, Varon D. Development, cell differentiation, angiogenesis-Microparticles and their roles in angiogenesis. Arterioscler Thromb Vasc Biol 2011;31:10-4.
61. Cochain C, Channon KM, Silvestre JS. Angiogenesis in the infarcted myocardium. Antioxid Redox Signal 2013;18:1100-13.
62. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67:30-8.
63. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004;124:376-84.
64. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of m RNA. Blood 2007;110:2440-8.
65. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002;160:673-80.
66. Lozito TP, Tuan RS. Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling. J Cell Physiol 2012;227:534-49.
67. Soleti R, Martinez MC. Sonic Hedgehog on microparticles and neovascularization. Vitam Horm 2012;88:395-438.
68. Soleti R, Benameur T, Porro C, Panaro MA, Andriantsitohaina R, Martínez MC. Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis 2009;30:580-8.
69. Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: Therapeutic potential. Circ Res 2011;109:110-9.
70. Yang C, Mwaikambo BR, Zhu T, Gagnon C, Lafleur J, Seshadri S, et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol 2008;294:R467-76.
71. Mostefai HA, Andriantsitohaina R, Martínez MC. Plasma membrane microparticles in angiogenesis: Role in ischemic diseases and in cancer. Physiol Res 2008;57:311-20.
72. Williams MS, Rogers HL, Wang NY, Ziegelstein RC. Do platelet-derived microparticles play a role in depression, inflammation, and acute coronary syndrome? Psychosomatics 2014;55:252-60.
73. Aliotta JM, Sanchez-Guijo FM, Dooner GJ, Johnson KW, Dooner MS, Greer KA, et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: A novel mechanism for phenotype modulation. Stem Cells 2007;25:2245-56.
74. Aliotta JM, Pereira M, Johnson KW, de Paz N, Dooner MS, Puente N, et al. Microvesicle entry into marrow cells mediates tissue-specific changes in m RNA by direct delivery of m RNA and induction of transcription. Exp Hematol 2010;38:233-45.
75. Quesenberry PJ, Dooner MS, Aliotta JM. Stem cell plasticity revisited: The continuum marrow model and phenotypic changes mediated by microvesicles. Exp Hematol 2010;38:581-92.
76. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFRv III by microvesicles derived from tumour cells. Nat Cell Biol 2008;10:619-24.
77. Caddeo C, Nácher A, Diez-Sales O, Merino-Sanjuan M, Fadda AM, Manconi M. Chitosan-xanthan gum microparticle-based oral tablet for colon-targeted and sustained delivery of quercetin. J Microencapsul 2014;31:694-9.
78. Maretti E, Rossi T, Bondi M, Croce MA, Hanuskova M, Leo E, et al. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis. Int J Pharm 2014;462:74-82.
79. Tantawy AA, Matter RM, Hamed AA, Shams El Din El Telbany MA. Platelet microparticles in immune thrombocytopenic purpura in pediatrics. Pediatr Hematol Oncol 2010;27:283-96.
80. Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, Adamson U, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 2010;126:e225-31.
81. Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gp IIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005;3:1168-71.
82. Mobarrez F, He S, Bröijersen A, Wiklund B, Antovic A, Antovic J, et al. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost 2011;106:344-52.
83. Montoro-Garcia S, Lip GY, Shantsila E. Atorvastatin and its collateral effects on microparticles. Thromb Haemost 2011;106:185-6.
84. Mobarrez F, Egberg N, Antovic J, Bröijersen A, Jörneskog G, Wallén H. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res 2012;129:95-7.
85. Shouzu A, Nomura S, Omoto S, Hayakawa T, Nishikawa M, Iwasaka T. Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus. Clin Appl Thromb Hemost 2004;10:167-73.
86. França CN, Pinheiro LF, Izar MC, Brunialti MK, Salomão R, Bianco HT, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 2012;76:729-36.
87. Bulut D, Becker V, Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol 2011;89:239-44.